TARDBP and amyotrophic lateral sclerosis: TAR6/6 mice are therefore an adequate model to test new compounds against ALS/FTLD that target TDP-43 overexpression, fragmentation, insolubility, neuroinflammation, motoneuron loss or other TDP-43 downstream signaling pathways.